Andere Sprachen Sana Biotechnology, Inc.

Aktien

A2QNUE

US7995661045

SANA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.05.2024			% 5 Tage	% 1. Jan.
7,8 ^USD	-2,74 %		-6,02 %	+91,18 %

21.05.	Sana Biotechnology, Inc. hebt die Veröffentlichung neuer präklinischer in-vivo-Daten in Nature Biotechnology hervor, die das Potenzial der Transplantation von aus pluripotenten Stammzellen gewonnenen menschlichen Glia-Vorläuferzellen zur Behandlung der Huntington-Krankheit und anderer neurodegenerativer Erkrankungen auf Glia-Basis zeigen	CI
15.05.	Transcript : Sana Biotechnology, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:00 PM

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions	21.05.
Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions	21.05.
Sana: Q1 Earnings Snapshot	08.05.
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates	08.05.
Sana Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Sana Biotechnology to Present at May and June 2024 Investor Conferences	06.05.
Sana Biotechnology, Inc. Announces Resignation of Douglas Williams as Executive Vice President and President, Research and Development	18.04.
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09.04.
Certain Restricted Stock Units of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	09.04.
Certain Stock Options of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	09.04.
Certain Common Stock of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	09.04.
Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows	01.03.
Sector Update: Health Care Stocks Edge Higher Premarket Friday	01.03.
Sana Biotechnology Q4 Non-GAAP Net Loss Narrows; Cash, Cash Equivalents Decline	29.02.
Sana: Q4 Earnings Snapshot	29.02.
Sana Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
Sana Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.02.
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	29.02.
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference	28.02.
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	16.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Sana Biotechnology, Inc.

Aktien

A2QNUE

US7995661045

SANA

Andere Sprachen

Filter